Serological Cytokine and chemokine profile in pregnant women with COVID19 in Mexico City

Abstract

On January 30th, 2020, the WHO declared the outbreak of COVID19, a disease due to the new coronavirus called SARS-CoV-2. Certain comorbidities, symptoms and signs are characteristic of COVID19 in the general population and in pregnant women. However, pregnant women are considered as a high-risk group for COVID19. To know about the frequency of comorbidities, signs and symptoms, the presence of lymphopenia, antibodies response to SARS-CoV2 and cytokine and chemokine serum concentration, six pregnant women with COVID19 were studied at the moment of admission. The lower concentration of CCL17 was detected in the Pregnant COVID19 group, similar concentration of IL-6 was also detected in non-pregnant and pregnant COVID19 patients. Our result show that pregnant and non-pregnant women with COVID19 has similar cytokine profile.

SARS-CoV-2 Infection and Inflammatory Response in a Twin Pregnancy

“…First, the mother was reported to have mild cholestasis of pregnancy, a condition associated with higher values of TNFa, IL1b, and Il-6 in the sera, and lower values of IL-4 and IL-10 [ 31 , 32 ]. Although expected, these current findings are counterbalanced by downregulation of IFNγ expression, which is reported as a hallmark of the antiviral response even in SARS-CoV-2 infection [ 33 ], being higher in pregnancy cholestasis [ 31 ] and more significant in patients infected with SARS-CoV-2 [ 34 ], as suggested in other reports [ 24 , 35 ]. On the other hand, IFNγ expression, along with IFN-α and IL-2 has been shown to be lower during influenza epidemic in pregnant women, when compared with nonpregnant women [ 36 ].…”

Impact of SARS‐CoV‐2 infection on risk of prematurity, birthweight and obstetric complications: A multivariate analysis from a nationwide, population‐based retrospective cohort study

“…One multicentre cohort study that was published after the meta‐analysis focused specifically on infected women; it reported an increased risk of prematurity, induced prematurity, severe infection, pre‐eclampsia and eclampsia (706 women with COVID‐19 versus 1424 without COVID‐19) 28 . These outcomes had already been suggested by previous studies and meta‐analyses 14,29–63 …”

“… 28 These outcomes had already been suggested by previous studies and meta‐analyses. 14 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 …”